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Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare though often fatal hyperinflammatory syndrome
mimicking sepsis in the critically ill. Diagnosis relies on the HLH-2004 criteria and HScore, both of which have been
developed in pediatric or adult non-critically ill patients, respectively. Therefore, we aimed to determine the
sensitivity and specificity of HLH-2004 criteria and HScore in a cohort of adult critically ill patients.
Methods: In this further analysis of a retrospective observational study, patients ≥ 18 years admitted to at least one
adult ICU at Charité – Universitätsmedizin Berlin between January 2006 and August 2018 with hyperferritinemia of
≥ 500 μg/L were included. Patients’ charts were reviewed for clinically diagnosed or suspected HLH. Receiver
operating characteristics (ROC) analysis was performed to determine prediction accuracy.
Results: In total, 2623 patients with hyperferritinemia were included, of whom 40 patients had HLH. We found the
best prediction accuracy of HLH diagnosis for a cutoff of 4 fulfilled HLH-2004 criteria (95.0% sensitivity and 93.6%
specificity) and HScore cutoff of 168 (100% sensitivity and 94.1% specificity). By adjusting HLH-2004 criteria cutoffs
of both hyperferritinemia to 3000 μg/L and fever to 38.2 °C, sensitivity and specificity increased to 97.5% and 96.1%,
respectively. Both a higher number of fulfilled HLH-2004 criteria [OR 1.513 (95% CI 1.372–1.667); p < 0.001] and a
higher HScore [OR 1.011 (95% CI 1.009–1.013); p < 0.001] were significantly associated with in-hospital mortality.
Conclusions: An HScore cutoff of 168 revealed a sensitivity of 100% and a specificity of 94.1%, thereby providing
slightly superior diagnostic accuracy compared to HLH-2004 criteria. Both HLH-2004 criteria and HScore proved to
be of good diagnostic accuracy and consequently might be used for HLH diagnosis in critically ill patients.
Clinical trial registration: The study was registered with www.ClinicalTrials.gov (NCT02854943) on August 1, 2016.
Keywords: Hemophagocytic lymphohistiocytosis (HLH), Macrophage activation syndrome (MAS), Hemophagocytic
syndrome (HPS), Intensive care unit (ICU), HLH-2004 criteria, HScore, Diagnosis
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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a hyper-
inflammatory syndrome caused by excessive cytokine re-
lease, triggered by genetic or acquired overactivation of
macrophages, T and natural killer (NK) cells [1]. Clinical
presentation may include fever, cytopenias, organome-
galy, and hyperferritinemia, none of which are specific
for this rare though life-threatening condition [2–4]. As
HLH shares similarities with other inflammatory states,
e.g., sepsis, its diagnosis is challenged by clinical overlap
particularly in the intensive care unit (ICU) [2]. Conse-
quently, HLH is likely to be under-recognized in critic-
ally ill patients where evidence for clear definition and
correct diagnostic workup is lacking [5]. So far, diagnosis
largely relies on data derived from studies conducted in
pediatric patients [6]. Henter et al. developed the HLH-
2004 criteria whereby a diagnosis of HLH is confirmed if
five out of eight criteria are fulfilled [7]. However, these
guidelines lack prospective validation in adult HLH pa-
tients. Moreover, the specificity of some criteria has been
questioned. According to HLH-2004 guidelines, a fer-
ritin ≥ 500 μg/L meets the criterion of hyperferritinemia
[7]. However, markedly higher ferritin levels have been
seen in adult HLH patients [8]. In fact, we detected best
prediction accuracy at a ferritin cutoff level of 9083 μg/L
with 92.5% sensitivity and 91.9% specificity for HLH in
critically ill patients, thereby providing satisfying dis-
crimination of HLH patients [8].
The HScore published by Fardet et al. [9] calculates a
sum score of nine variables allowing to assess the prob-
ability of HLH. Each variable was assigned a maximum
number varying between 18 and 64 points. The authors
found the best discriminatory performance at an HScore
of 169 with a sensitivity of 93.0% and specificity of 86.0%.
Unlike the HLH-2004 criteria which are composed of pa-
rameters derived from a pediatric population, the HScore
was developed in an adult cohort including patients aged
≥ 18 years. Yet, only non-ICU patients were included, pos-
sibly limiting the tool’s generalizability to critically ill pa-
tients. Hence, it is unclear whether HLH-2004 criteria and
HScore reliably detect and discriminate HLH in adult crit-
ically ill patients. We therefore calculated the sensitivity
and specificity of HLH-2004 criteria and HScore, respect-




This further analysis of a retrospective observational study
[8] was conducted at the university hospital Charité –
Universitätsmedizin Berlin. Data of patients who were ad-
mitted to at least one adult surgical, anesthesiological, or
medical ICU between January 2006 and August 2018 were
reviewed and extracted from two electronic patient data
management systems operated at the Charité – Universi-
tätsmedizin Berlin (COPRA, Sasbachwalden, Germany
and SAP, Walldorf, Germany). We included all patients
aged ≥ 18 years who had at least one ferritin value mea-
sured during ICU stay and hyperferritinemia of at least
500 μg/L according to HLH-2004 criteria [7]. Of all pa-
tients included, we extracted data for body temperature,
ferritin, blood counts, triglycerides, fibrinogen, soluble
interleukin-2 receptor (sIL-2R), and aspartate aminotrans-
ferase (AST). Ultrasound, computed tomography (CT)
scans and autopsy findings were reviewed to determine
the presence of hepatomegaly and/or splenomegaly. Med-
ical reports were screened for evidence of preexisting im-
munosuppression, while bone marrow findings were
reviewed for hemophagocytosis. All variables were re-
corded at day of maximum ferritin assessment. If no as-
sessment was documented that day, we extended the
period to a plausible time range for each parameter ac-
cording to our protocol (Table 1). Using the obtained
data, HLH-2004 criteria and HScore (Supplement Table
S1) were determined in all non-HLH patients. To avoid
bias by pending parameters at the day of ferritin max-
imum, we used the highest number of fulfilled HLH-2004
criteria and maximum HScore in all HLH patients. The
study period was defined from ICU admission until hos-
pital discharge, transfer, or death.
Diagnosis of HLH
The charts of all included patients were reviewed for clinic-
ally diagnosed or suspected HLH. In parallel, we searched
for all adult ICU patients diagnosed with ICD-10 codes for
HLH (D76.1, D76.2, and D76.3). Only cases with previously
suspected or diagnosed HLH by clinicians were reviewed
by two HLH experts who confirmed or rejected HLH
Table 1 Data collection of variables for HLH-2004 criteria and
HScore
Variables Time range with regard to maximum
ferritin (when not assessed at day of
ferritin maximum)
Hemoglobin, platelets, white
blood cell count [min]
± 3 days
Fibrinogen [min] ± 3 days
Triglycerides [max] ± 5 days
Body temperature [max] ± 5 days
AST [max] ± 3 days
NK cell activity, CD107a [max] ± 10 days
sIL-2R Study period
Hepatomegaly, splenomegaly Study period
Hemophagocytosis Study period
Preexisting immunosuppression Obtained from medical records
before study period
AST aspartate aminotransferase, Max maximum, Min minimum, NK natural
killer cell, sIL-2R soluble interleukin-2 receptor
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diagnosis based on HLH-2004 criteria and HScore (Supple-
ment Table S1) while considering patient’s history and clin-
ical presentation, according to current recommendations
[6]. Importantly, the diagnosis of HLH was confirmed be-
fore HLH-2004 criteria and HScore were determined in all
non-HLH patients, i.e., patients who were not previously di-
agnosed or suspected for HLH by clinicians. Though HLH-
2004 criteria and HScore were determined in latter patients,
these were not reviewed for HLH by the experts. Of note,
HLH patients comprise 7 cases of previously undiagnosed
HLH who have been retrospectively detected and described
by our research group [5].
Statistical analysis
Results are reported as median (percentiles) or as counts
(relative frequencies) according to their scaling. Com-
parison of HLH and non-HLH patients was conducted
using the non-parametric Mann-Whitney U test for con-
tinuous variables and the chi-square test for categorical
variables. Receiver operating characteristics (ROC) ana-
lysis was performed to determine the best prediction ac-
curacy of each diagnostic variable for HLH diagnosis
and for fixed combinations. As a post hoc analysis, we
rerun ROC analyses for HLH-2004 criteria while raising
hyperferritinemia cutoff from 500 to 3000 μg/L based on
the lowest ferritin maximum in HLH patients (3102 μg/
L). To analyze the best fever cutoff, we reiterated ROC
analyses for HLH-2004 criteria using fever cutoffs from
38.0 to 38.5 °C (38.3 °C was used for main analyses as
shown in Supplement Table S1). For analysis of hepato-
megaly, we extended splenomegaly to spleno- and/or
hepatomegaly in another post hoc ROC analyses for
HLH-2004 criteria. As a sensitivity analysis, we rerun
ROC analyses for HLH-2004 criteria and HScore with
restriction to patients with at least 5 assessed HLH-2004
criteria. Multivariable logistic regression analysis was
performed to assess associations between HLH-2004 cri-
teria and HScore, respectively, with in-hospital mortality
while adjusting for age, sex, body mass index (BMI), and
maximum sequential organ failure assessment (SOFA)
score. All tests should be understood as constituting ex-
ploratory data analysis. No adjustments for multiple test-
ing were made. A two-tailed P value < 0.05 was
considered statistically significant. All numerical calcula-
tions were performed with IBM© SPSS© Statistics, Ver-
sion 26, © Copyright 1989, 2010 SPSS Inc.
Results
Study population and characteristics
Between January 2006 and August 2018, 6340 of 116,310
ICU patients had at least one ferritin measurement during
ICU stay and were ≥ 18 years old. Of these, 2623 patients
with hyperferritinemia (≥ 500 μg/L) were included into the
final analyses. Among those, 50 patients had initially been
diagnosed or suspected with HLH by clinicians of whom 40
cases were confirmed by the experts (Fig. 1). The remaining
Fig. 1 Consort diagram
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10 patients (Supplement Table S2) had either low number
of fulfilled HLH-2004 criteria (< 4) or low HScore (< 190);
in three of the 50 patients, clinical judgment was decisive.
Basic patient characteristics, values of HLH-2004 criteria
and HScore, and outcome parameters are shown in Table 2.
Distribution of fulfilled HLH-2004 criteria and HScore over
all patients is shown in Fig. 2. The group of HLH patients
has been described in detail previously [4]. The overall co-
hort of 2623 patients has already been published [8] to
analyze hyperferritinemia between patients with HLH, sep-
sis, septic shock, and other diagnoses.
Sensitivity and specificity of HLH-2004 criteria and HScore
Twenty-nine HLH patients (72.5%) and 33 non-HLH pa-
tients (1.3%) fulfilled at least 5 HLH-2004 criteria. ROC
curves of fulfilled HLH-2004 criteria and HScore are
shown in Fig. 3. The best prediction accuracy for HLH
was seen for a cutoff of 4 fulfilled HLH-2004 criteria and
an HScore cutoff of 168. The sensitivity and specificity
of each criterion are shown in Table 3, while the ana-
lyses of ferritin and sIL-2R were already published in
Lachmann et al. [8]. When analyses were restricted to
patients with at least 5 measured HLH-2004 criteria
Table 2 Basic patient characteristics, biomarkers, and outcome parameters
Parameters HLH patients (n = 40) Non-HLH patients (n = 2583) P value
Age [years] 47 (33–62) 62 (49–73) < 0.001‡
Male sex [n] (%) 26 (65.0%) 1588 (61.5%) 0.650†
Body mass index [kg/m2] 23.0 (21.0–26.5) 25.0 (22.0–29.0) 0.094‡
Sepsis without shock [n] (%) 12 (30.0%) 1003 (38.8%) 0.255†
Septic shock [n] (%) 23 (57.5%) 626 (24.2%) < 0.001†
Hemodialysis [n] (%) 29 (72.5%) 1357 (52.5%) 0.012†
ECLA/ECMO [n] (%) 6 (15.0%) 188 (7.3%) 0.064†
ICU admission SOFA score 9 (6–13) 6 (3–9) < 0.001‡
Maximum SOFA score 17 (12–19) 11 (7–15) < 0.001‡
HLH-2004 criteria
Measured 7 (6–7) 4 (4–5) < 0.001‡
Fulfilled 5 (4–6) 2 (1–2) < 0.001‡
HScore 258 (225–280) 62 (33–101) < 0.001‡
Bi-/pancytopenia [n] (%)*, n = 40|2582 37 (92.5%) 471 (18.2%) < 0.001†
Hemoglobin [g/dL] 6.9 (6.4–7.6) 8.8 (7.9–9.9) < 0.001‡
Platelet count [/nL] 18 (5–34) 170 (88–270) < 0.001‡
Leukocyte count [/nL] 0.9 (0.2–2.7) 9.0 (6.1–13.3) < 0.001‡
Hypofibrinogenemia or hypertriglyceridemia [n] (%), n = 40|1517 30 (75.0%) 288 (19.0%) < 0.001†
Fibrinogen [mg/dL], n = 39|1144 2.0 (1.0–3.0) 3.8 (2.5–5.3) < 0.001‡
Triglycerides [mg/dL], n = 39|855 376 (245–563) 158 (104–247) < 0.001‡
Max. core body temperature [°C], n = 40|2452 39.1 (38.5–39.8) 38.2 (37.5–38.9) < 0.001†
Splenomegaly [n] (%), n = 40|2008 26 (65.0%) 401 (20.0%) < 0.001†
Hepatomegaly [n] (%), n = 40|2037 23 (57.5%) 328 (16.1%) < 0.001†
Hemophagocytosis [n] (%), n = 31|221 16 (51.6%) 15 (6.8%) < 0.001†
AST [U/L], n = 40|2327 171 (119–498) 47 (26–108) < 0.001‡
Pre-existing immunosuppression [n] (%) 30 (75.0%) 728 (28.2%) < 0.001†
ICU duration [d] 20.0 (11.3–37.3) 19.0 (6.0–47.1) 0.522‡
In-patient duration [d] 27.7 (18.6–77.4) 38.3 (18.1–76.1) 0.682‡
Deceased [n] 24 (60.0%) 741 (28.7%) < 0.001†
Diagnostic parameters with n representing the number of patients with available data in each group, if not available in all patients; continuous quantities in
median with quartiles. CD107a testing as a functional marker for identification of NK cell activity was performed in 4 patients only; however, three showed values
within the normal range and one could not be analyzed due to low NK cell count. Values of ferritin and sIL-2R of the cohort were already described in Lachmann
et al. [8]
ECLA extracorporeal lung assist, ECMO extracorporeal membrane oxygenation, ICU intensive care unit, SOFA sequential organ failure assessment
‡P values calculated using the Mann-Whitney U test
†P values calculated using the χ2 test
*Leukopenia was assumed by white blood cell count < 1.67/nL
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(n = 1303), we found 95.0% sensitivity and 88.0% specifi-
city for the cutoff of 4 fulfilled HLH-2004 criteria (AUC
0.968 (95% CI 0.950–0.986)) as well as 100% sensitivity
and 88.6% specificity for the HScore cutoff of 168 (AUC
0.984 (95% CI 0.975–0.993)).
Post hoc analyses of HLH-2004 criteria cutoffs
When hyperferritinemia cutoff was raised from 500 to
3000 μg/L, the specificity of 4 fulfilled HLH-2004 criteria
increased to 96.1%, while sensitivity remained 95.0%
(AUC 0.989 (95% CI 0.983–0.996)). By analyses of differ-
ent fever cutoffs, best prediction accuracy was found for
38.2 °C (97.5% sensitivity and 93.5% specificity for 4 ful-
filled HLH-2004 criteria (AUC 0.984 (95% CI 0.975–
0.994))). By adjusting cutoffs of both hyperferritinemia
to 3000 μg/L and fever to 38.2 °C, the sensitivity and spe-
cificity of 4 fulfilled HLH-2004 criteria were 97.5% and
96.1%, respectively (AUC 0.991 (95% CI 0.985–0.996)).
Extension of splenomegaly to spleno- and/or hepato-
megaly reduced specificity of 4 fulfilled HLH-2004
Fig. 2 Distribution of fulfilled HLH-2004 criteria and HScore over all patients
Fig. 3 Receiver operating characteristic curves of fulfilled HLH-2004 criteria and HScore
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criteria from 93.6 to 92.2% while the sensitivity of 95.0%
was unchanged (AUC 0.981 (95% CI 0.968–0.993)). Ana-
lyses of fixed combinations of fulfilled HLH-2004 criteria
showed less prediction accuracy compared to independ-
ent combinations of at least 4 fulfilled HLH-2004 criteria
(Supplement Table S3).
HLH-2004 criteria and HScore for prediction of mortality
Multivariable logistic regression analysis including age,
sex, BMI, and maximum SOFA score as confounders re-
vealed statistically significant associations between in-
hospital mortality and fulfilled HLH-2004 criteria or
HScore, respectively (Table 4). In-hospital mortality of
Table 3 Sensitivity and specificity of fulfilled HLH-2004 criteria and HScore
Parameters AUC (95% CI) Cutoff Sensitivity/specificity















Bi-/pancytopenia 0.871 (0.822–0.920) Yes 92.5%/81.8%
Hypofibrinogenemia or hypertriglyceridemia 0.780 (0.702–0.859) Yes 75.0%/81.0%
Fibrinogen [g/L] 0.760 (0.677–0.843) 1.5 43.6%/91.1%
3.1 79.5%/64.5%
Triglycerides [mg/dL] 0.830 (0.776–0.883) 229 84.6%/71.9%
265 66.7%/77.4%
Max. core body temperature [°C] 0.737 (0.656–0.818) 38.5 80.0%/59.8%
Splenomegaly 0.725 (0.638–0.812) Yes 65.0%/80.0%
Hemophagocytosis 0.724 (0.611–0.837) Yes 51.6%/93.2%
Receiver operating characteristics (ROC) analysis to determine the best prediction accuracy of each diagnostic variable for HLH diagnosis. CD107a testing as a
functional marker for identification of NK cell activity not shown as performed in 4 patients only. The predictive values of ferritin and sIL-2R of the cohort were
already analyzed in Lachmann et al. [8]
AUC Area under the curve, CI confidence interval
Table 4 Multivariable logistic regression analyses for in-hospital mortality
Covariates HLH-2004 criteria HScore
OR 95% CI P value OR 95% CI P value
Age, years 1.025 1.018–1.031 < 0.001 1.031 1.024–1.038 < 0.001
Sex (male) 0.943 0.778–1.143 0.550 0.897 0.737–1.091 0.276
BMI, kg/m2 0.979 0.965–0.994 0.005 0.980 0.965–0.995 0.009
SOFA score max 1.163 1.140–1.185 < 0.001 1.148 1.126–1.171 < 0.001
Fulfilled HLH-2004 criteria 1.513 1.372–1.667 < 0.001 –
HScore – 1.011 1.009–1.013 < 0.001
Multivariable logistic regression analyses were performed with in-hospital death as dependent variable
BMI body mass index, CI confidence interval, OR odds ratio, SOFA sequential organ failure assessment
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fulfilled HLH-2004 criteria and HScore strata is shown
in Supplement Table S4.
Discussion
This is the largest study investigating the diagnostic per-
formance of HLH-2004 criteria and HScore in an adult
intensive care population. We found the best prediction
accuracy of HLH diagnosis for a cutoff of 4 fulfilled
HLH-2004 criteria (95.0% sensitivity and 93.6% specifi-
city) and an HScore cutoff of 168 (100% sensitivity and
94.1% specificity). Analyses of each single HLH-2004 cri-
terion revealed good sensitivity and specificity for a fer-
ritin cutoff of 9083 μg/L described previously [8] while
all other HLH-2004 criteria had unsatisfying predictive
ability in our study, including sIL-2R, which was also de-
scribed previously [8]. The combination of 4 fulfilled
HLH-2004 criteria provided better diagnostic accuracy
compared to each single criterion. By adjusting HLH-
2004 criteria cutoffs of both hyperferritinemia to
3000 μg/L and fever to 38.2 °C, sensitivity and specificity
increased to 97.5 and 96.1%, respectively. Our approach
to analyze fixed combinations of fulfilled HLH-2004 cri-
teria showed less prediction accuracy compared to inde-
pendent combinations of at least 4 fulfilled HLH-2004
criteria. Both HLH-2004 criteria and HScore were inde-
pendently associated with in-hospital mortality.
The HLH-2004 criteria, currently the standard in HLH
diagnosis, have been developed in pediatric populations
but so far have not been validated in adult patients. Ac-
cording to current recommendations for HLH in adults,
HLH diagnosis requires ≥ 5 fulfilled HLH-2004 criteria
which should be considered along with patient’s history
and clinical presentation [6]. In daily practice, clinical
presentation might be suggestive of HLH, while less than
5 out of 8 HLH-2004 criteria are present. Moreover, the
diagnostic value of some criteria, e.g., fever, is limited,
particularly in critically ill patients where the use of anti-
pyretic agents and devices such as extracorporeal mem-
brane oxygenation (ECMO) and hemodialysis are
frequently seen rendering body temperature an unreli-
able or even invalid parameter. Of note, the cutoff of 4
fulfilled HLH-2004 criteria had the best sensitivity and
specificity possibly allowing faster HLH diagnosis,
prompt treatment, and thus improved survival. Yet,
these findings need further confirmation in prospective
studies to validate safe HLH diagnosis in adults with
only 4 fulfilled HLH-2004 criteria. Ongoing studies
could contribute to improve safe HLH diagnosis in adult
critically ill patients [10].
Our analysis of sensitivity and specificity of single
HLH-2004 criteria is broadly in line with data reported
in pediatric HLH patients. Hypofibrinogenemia is known
to have high specificity but rather low sensitivity as only
53% of children with HLH had fibrinogen levels < 1.5 g/
L [11]. Also, we found sensitivity for fibrinogen of 1.5 g/
L to be at 43.6% while specificity was at 91.1%. In con-
trast to studies in pediatric populations, sIL-2R proves
to be of insufficient diagnostic value in adult patients [8]
whereas levels ≥ 2400 U/L in children provided good
sensitivity and excellent specificity of 93.0% and 100%,
respectively [11]. The diagnostic value of ferritin in the
present cohort has been described previously by our re-
search group and appeared as a good screening
marker [8]. Importantly, the presence of 4 fulfilled HLH-
2004 criteria provides higher sensitivity and specificity
for HLH diagnosis than ferritin alone. Of note, sensitiv-
ity and specificity of 4 fulfilled HLH-2004 criteria in-
creased to 97.5% and 96.1%, respectively, when cutoffs of
both hyperferritinemia and fever were adjusted to
3000 μg/L and 38.2 °C, respectively. In this context it is
noteworthy that 5 out of 8 HLH-2004 criteria can be ful-
filled in critically ill non-HLH patients. NK cell activity
was assessed in four patients only in whom HLH was
likely considered as a differential diagnosis. For practical
guidance, we recommend assessment of body
temperature, cytopenias, ferritin, triglycerides, fibrino-
gen, splenomegaly, and wherever available sIL-2R.
Hemophagocytosis, even though the eponymous feature
of HLH with high specificity, is an unreliable diagnostic
marker with only poor sensitivity, again particularly in
critically ill patients with sepsis [12]. However, the latest
recommendations for HLH in adult patients advise bone
marrow investigation as it helps to detect occult
hemato-oncological malignancies and to differentiate be-
tween cytopenias caused by chemotherapy from patients
who have actually underlying HLH [6]. The HScore de-
veloped by Fardet et al. [9] provides a tool to predict the
probability of HLH diagnosis in adults. The authors
found the best cutoff at an HScore of 169 yielding 93.0%
sensitivity and 86.0% specificity in a cohort of non-ICU
patients. Our present study included ICU patients only
and revealed an HScore of 168 to have the best sensitiv-
ity and specificity of 100% and 94.1%, respectively,
thereby providing slightly superior prediction accuracy
compared to the HLH-2004 criteria. Importantly, the
similar found cutoff underlines the value of the HScore
for HLH diagnosis and its reliability in critically ill
patients.
One previous study by Meena et al. [13] also analyzed
the diagnostic performance of HLH-2004 criteria and
HScore in critically ill patients. The authors included
445 patients with ferritin assessment among whom ten
were diagnosed with HLH. They reported an HScore of
143.5 for best possible classification and found 5 out of
6 criteria to be the cutoff for HLH-2004 criteria with
70% and sensitivity and 97.2% specificity. However, we
present a larger cohort of 2623 patients including 40
HLH cases. Yet, the work by Meena et al. and our study
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are currently the only data available investigating the
diagnostic standard for HLH diagnosis in the adult ICU
population.
Both HLH-2004 criteria and HScore were associated
with in-hospital mortality suggesting that both indicate
disease severity. This relationship has been reported pre-
viously by Gualdoni et al. who found increased 30-day
mortality correlating with HLH-2004- or HScore-
positive patients [14].
Our study has several limitations. As this is a retro-
spective study, data availability had to rely on patients
who had a ferritin assessment during their ICU stay.
This might constitute an important selection bias as pa-
tients with ferritin assessment might have been more se-
verely ill. For instance, suspicion of inflammation or
diagnostic of anemia was likely when ferritin assessment
was considered. Thus, our findings might not be
generalizable to ICU patients without hyperferritinemia.
In addition, not all variables of HLH-2004 criteria and
HScore were available in all patients which reflects clin-
ical practice where rather rare diagnostic tests such as
NK cell activity might be unavailable. Our study bears a
considerable risk that HLH cases could have remained
undiagnosed depending on physicians’ expertises, par-
ticularly in patients with ≥ 5 fulfilled HLH-2004 criteria.
Conclusions
This is currently the largest study investigating the diag-
nostic performance of HLH-2004 criteria and HScore in
an adult ICU cohort. Four fulfilled HLH-2004 criteria as
cutoff for a diagnosis of HLH had a sensitivity of 95.0%
and a specificity of 93.6%. By adjusting cutoffs of both
hyperferritinemia to 3000 μg/L and fever to 38.2 °C, sen-
sitivity and specificity increased to 97.5% and 96.1%, re-
spectively. An HScore cutoff of 168 revealed a sensitivity
of 100% and a specificity of 94.1%, thereby providing
slightly superior diagnostic accuracy compared to HLH-
2004 criteria. With regard to single criteria, ferritin dem-
onstrated the best diagnostic performance of all 8 HLH-
2004 criteria warranting its use as a reliable screening
parameter for HLH diagnosis. Both HLH-2004 criteria
and HScore proved to be of good diagnostic accuracy
and consequently might be used for HLH diagnosis in
critically ill patients.
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